Does the media prefer IMRX or SERA?

In the previous week, Immuneering and Immuneering both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat Immuneering's score of -0.64 indicating that Sera Prognostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IRD or SERA more profitable?

Opus Genetics has a net margin of -1,091.82% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Opus Genetics' return on equity. Company Net Margins Return on Equity Return on Assets Opus Genetics -1,091.82% -338.88% -150.13% Sera Prognostics -47,475.72% -46.71% -34.06%

Does the media prefer IRD or SERA?

In the previous week, Opus Genetics had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Opus Genetics and 1 mentions for Sera Prognostics. Opus Genetics' average media sentiment score of 0.66 beat Sera Prognostics' score of 0.59 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SERA or YDES?

Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 177.78%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sera Prognostics is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, SERA or YDES?

YD Bio has lower revenue, but higher earnings than Sera Prognostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sera Prognostics $80K 976.39 -$31.93M -$0.67 N/A YD Bio N/A N/A N/A N/A N/A

Is SERA or YDES more profitable?

YD Bio has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. YD Bio's return on equity of 0.00% beat Sera Prognostics' return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -47,475.72% -46.71% -34.06% YD Bio N/A N/A N/A

Does the media refer more to SERA or YDES?

In the previous week, YD Bio had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for YD Bio and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat YD Bio's score of 0.32 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive YD Bio 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SERA or SABS?

In the previous week, Sera Prognostics and Sera Prognostics both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat SAB Biotherapeutics' score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sera Prognostics (SERA) Competitors

$1.98 -0.03 (-1.49%)

As of 04:00 PM Eastern

Compare

SERA vs. STRO, IMRX, IRD, YDES, and SABS

Should you buy Sera Prognostics stock or one of its competitors? Sera Prognostics's main competitors and comparable companies include Sutro Biopharma (STRO), Immuneering (IMRX), Opus Genetics (IRD), YD Bio (YDES), and SAB Biotherapeutics (SABS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sera Prognostics compare to Sutro Biopharma?

Sera Prognostics (NASDAQ:SERA) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Sera Prognostics presently has a consensus target price of $5.50, indicating a potential upside of 177.78%. Sutro Biopharma has a consensus target price of $47.30, indicating a potential upside of 130.28%. Given Sera Prognostics' higher probable upside, equities research analysts plainly believe Sera Prognostics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Sera Prognostics had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 1 mentions for Sera Prognostics and 0 mentions for Sutro Biopharma. Sera Prognostics' average media sentiment score of 0.59 beat Sutro Biopharma's score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Overall Sentiment
Sera Prognostics	Positive
Sutro Biopharma	Neutral

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sera Prognostics has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Sutro Biopharma has a net margin of -395.25% compared to Sera Prognostics' net margin of -47,475.72%. Sutro Biopharma's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Sutro Biopharma	-395.25%	N/A	-88.12%

Sera Prognostics has higher earnings, but lower revenue than Sutro Biopharma. Sera Prognostics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	976.39	-$31.93M	-$0.67	N/A
Sutro Biopharma	$102.48M	3.32	-$191.09M	-$11.97	N/A

Summary

Sutro Biopharma beats Sera Prognostics on 9 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Immuneering has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Immuneering's return on equity of -27.15% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-27.15%	-25.75%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Immuneering presently has a consensus price target of $17.50, suggesting a potential upside of 247.22%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 177.78%. Given Immuneering's stronger consensus rating and higher probable upside, equities analysts clearly believe Immuneering is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

67.7% of Immuneering shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 14.9% of Immuneering shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sera Prognostics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A
Sera Prognostics	$80K	976.39	-$31.93M	-$0.67	N/A

In the previous week, Immuneering and Immuneering both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat Immuneering's score of -0.64 indicating that Sera Prognostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immuneering has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Summary

Immuneering beats Sera Prognostics on 9 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Sera Prognostics has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	26.77	-$49.59M	-$1.35	N/A
Sera Prognostics	$80K	976.39	-$31.93M	-$0.67	N/A

Opus Genetics currently has a consensus target price of $10.69, indicating a potential upside of 132.44%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 177.78%. Given Sera Prognostics' higher probable upside, analysts clearly believe Sera Prognostics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Opus Genetics had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for Opus Genetics and 1 mentions for Sera Prognostics. Opus Genetics' average media sentiment score of 0.66 beat Sera Prognostics' score of 0.59 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Opus Genetics has a net margin of -1,091.82% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Opus Genetics has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Summary

Sera Prognostics beats Opus Genetics on 9 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to YD Bio?

Sera Prognostics (NASDAQ:SERA) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, YD Bio had 5 more articles in the media than Sera Prognostics. MarketBeat recorded 6 mentions for YD Bio and 1 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.59 beat YD Bio's score of 0.32 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
YD Bio	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sera Prognostics presently has a consensus target price of $5.50, suggesting a potential upside of 177.78%. Given Sera Prognostics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sera Prognostics is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

YD Bio has lower revenue, but higher earnings than Sera Prognostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	976.39	-$31.93M	-$0.67	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

YD Bio has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. YD Bio's return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
YD Bio	N/A	N/A	N/A

54.6% of Sera Prognostics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Sera Prognostics beats YD Bio on 8 of the 12 factors compared between the two stocks.

How does Sera Prognostics compare to SAB Biotherapeutics?

Sera Prognostics (NASDAQ:SERA) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Sera Prognostics has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

SAB Biotherapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. SAB Biotherapeutics' return on equity of -6.74% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
SAB Biotherapeutics	N/A	-6.74%	-6.06%

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 7.4% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sera Prognostics presently has a consensus price target of $5.50, indicating a potential upside of 177.78%. SAB Biotherapeutics has a consensus price target of $12.00, indicating a potential upside of 222.58%. Given SAB Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe SAB Biotherapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

SAB Biotherapeutics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	976.39	-$31.93M	-$0.67	N/A
SAB Biotherapeutics	$1.32M	256.43	$13.27M	-$1.30	N/A

In the previous week, Sera Prognostics and Sera Prognostics both had 1 articles in the media. Sera Prognostics' average media sentiment score of 0.59 beat SAB Biotherapeutics' score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

SAB Biotherapeutics beats Sera Prognostics on 9 of the 16 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$79.29M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-2.96	12.66	273.28	25.38
Price / Sales	976.39	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	1.31	16.29	12.89	6.14
Net Income	-$31.93M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-2.46%	-1.37%	-0.33%	-1.47%
1 Month Performance	-5.71%	11.07%	6.51%	2.47%
1 Year Performance	-41.76%	53.71%	25.19%	15.84%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	2.5714 of 5 stars	$1.98 -1.5%	$5.50 +177.8%	-39.6%	$79.29M	$80K	N/A	120
STRO Sutro Biopharma	2.4387 of 5 stars	$21.44 +4.6%	$47.30 +120.6%	+115.2%	$339.75M	$102.48M	N/A	240
IMRX Immuneering	3.1932 of 5 stars	$5.23 +1.0%	$17.50 +234.6%	-16.2%	$335.13M	N/A	N/A	60
IRD Opus Genetics	2.7448 of 5 stars	$4.11 +2.0%	$10.69 +160.2%	+261.8%	$333.07M	$14.20M	N/A	14	News Coverage Gap Up
YDES YD Bio	N/A	$4.68 +0.4%	N/A	N/A	$329.88M	N/A	N/A	N/A	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. STRO, IMRX, IRD, YDES, and SABS

How does Sera Prognostics compare to Sutro Biopharma?

Summary

How does Sera Prognostics compare to Immuneering?

Summary

How does Sera Prognostics compare to Opus Genetics?

Summary

How does Sera Prognostics compare to YD Bio?

Summary

How does Sera Prognostics compare to SAB Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. STRO, IMRX, IRD, YDES, and SABS

How does Sera Prognostics compare to Sutro Biopharma?

Do analysts recommend SERA or STRO?

Does the media refer more to SERA or STRO?

Do institutionals & insiders have more ownership in SERA or STRO?

Which has more risk & volatility, SERA or STRO?

Is SERA or STRO more profitable?

Which has higher valuation & earnings, SERA or STRO?

Summary

How does Sera Prognostics compare to Immuneering?

Is IMRX or SERA more profitable?

Do analysts prefer IMRX or SERA?

Do insiders and institutionals believe in IMRX or SERA?

Which has preferable earnings & valuation, IMRX or SERA?

Does the media prefer IMRX or SERA?

Which has more risk and volatility, IMRX or SERA?

Summary

How does Sera Prognostics compare to Opus Genetics?

Which has better earnings & valuation, IRD or SERA?

Do analysts prefer IRD or SERA?

Does the media prefer IRD or SERA?

Do insiders & institutionals have more ownership in IRD or SERA?

Is IRD or SERA more profitable?

Which has more volatility & risk, IRD or SERA?

Summary

How does Sera Prognostics compare to YD Bio?

Does the media refer more to SERA or YDES?

Do analysts recommend SERA or YDES?

Which has stronger valuation & earnings, SERA or YDES?

Is SERA or YDES more profitable?

Do institutionals & insiders hold more shares of SERA or YDES?

Summary

How does Sera Prognostics compare to SAB Biotherapeutics?

Which has more volatility & risk, SERA or SABS?

Is SERA or SABS more profitable?

Do institutionals & insiders believe in SERA or SABS?

Do analysts recommend SERA or SABS?

Which has preferable valuation & earnings, SERA or SABS?

Does the media refer more to SERA or SABS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools